Biocure Technology Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing biosimilar technologies for cancer treatment. The Companyâ€™s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Canadian Securities Exchange 11:46:42 2026-07-29 EDT			5-day change	1st Jan Change
0.0550 ^CAD	-21.43%		-.--%	-26.67%

08-28	Biocure Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-21	Glorious Success Limited signed a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE.X) for in a reverse merger transaction.	CI

Market Cap	1.11M 779K 696K 650K 590K 75.39M 1.12M 7.81M 3.05M 38.34M 2.93M 2.86M 123M	P/E 2024	-0.6x	P/E 2025	-11.5x
Enterprise Value	1.13M 791K 707K 660K 599K 76.56M 1.14M 7.93M 3.1M 38.94M 2.97M 2.91M 125M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	96.58%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Canadian Securities Exchange	CURE.X	Delayed
Deutsche Boerse AG	1WH0	Delayed

08-28	Biocure Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-21	Glorious Success Limited signed a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE.X) for in a reverse merger transaction.	CI
04-15	Biocure Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-13	Biocure Technology Inc. Auditor Raises 'Going Concern' Doubt	CI
11-28	Biocure Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-26	Biocure Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-30	Biocure Technology Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-05-29	Biocure Technology Inc. announced that it has received CAD 0.1 million in funding	CI
25-05-02	Biocure Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-05-02	Biocure Technology Inc. Auditor Raises 'Going Concern' Doubt	CI
25-04-20	Biocure Technology Inc. cancelled the transaction announced on December 19, 2024	CI
25-04-20	Biocure Technology Inc. announced that it expects to receive CAD 0.15 million in funding	CI
24-12-18	Biocure Technology Inc. announced that it expects to receive CAD 0.2 million in funding	CI

Biocure Technology Inc. Stock

Stocks

CURE.X

CA09075T2065

Pharmaceuticals

Valuation: Biocure Technology Inc.

Chart: Biocure Technology Inc.

Latest news: Biocure Technology Inc.

Press Releases: Biocure Technology Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Biocure Technology Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

08-12	Biocure Technology Inc. enters into Definitive Share Exchange Agreement to acquire Glorious Success Limited	AQ
08-11	Canadian Investment Regulatory Organization Trading Halt - CURE.X	AQ
06-23	Canadian Investment Regulatory Organization Trade Resumption - CURE.X	AQ
06-22	Canadian Investment Regulatory Organization Trading Halt - CURE.X	AQ
24-10-23	CSE Bulletin: Consolidation - Biocure Technology Inc. (CURE.X)	NE

1 day	-21.43%
3 months	-15.38%
6 months	+57.14%
Current year	-26.67%

Current year	0.04	0.09
1 year	0.03	0.24
3 years	0.01	0.32
5 years	0.01	1.89
10 years	0.01	17.01

Manager	Title	Age	Since
Yee Sing Cheng CEO	Chief Executive Officer	44	2023-09-07
Konstantin Lichtenwald DFI	Director of Finance/CFO	42	2018-02-28

Director	Title	Age	Since
Collin Kim BRD	Director/Board Member	60	2015-08-27
Konstantin Lichtenwald BRD	Director/Board Member	42	2018-02-28
Yee Sing Cheng BRD	Director/Board Member	44	2023-09-07

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
7/8/25	Simon Cheng	Sell		500,000	4.7872%
7/8/25	Simon Cheng	Other		0	0%	-
7/8/25	Collin Kim	Sell	Director	1,600,000	15.3191%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOCURE TECHNOLOGY INC.	-21.43%	-.--%	-8.33%	-59.26%	782K
ELI LILLY AND COMPANY	+3.23%	+3.36%	+41.76%	+109.17%	1,032B
JOHNSON & JOHNSON	+1.83%	-2.03%	+37.32%	+63.60%	614B
ABBVIE INC.	+2.11%	+4.26%	+17.14%	+82.91%	471B
MERCK & CO., INC.	+0.75%	-1.78%	+62.90%	+36.57%	350B
ROCHE HOLDING AG	+2.92%	+3.12%	+24.78%	+43.51%	337B
NOVARTIS AG	+2.42%	+0.05%	+14.13%	+36.19%	268B
ASTRAZENECA PLC	+1.86%	-0.81%	-4.69%	+12.20%	246B
AMGEN INC.	+2.64%	-2.21%	+39.47%	+51.80%	218B
GILEAD SCIENCES, INC.	+2.19%	-1.10%	+26.22%	+96.38%	179B
Average	-0.34%	-3.05%	+25.07%	+47.31%	371.48B
Weighted average by Cap.	+2.25%	-3.18%	+32.40%	+69.84%

	2024	2025
Net sales	-	-
Net income	-262K -184K -164K -153K -139K -17.8M -264K -1.84M -720K -9.05M -691K -676K -29.11M	-103K -72.13K -64.45K -60.13K -54.62K -6.98M -104K -723K -282K -3.55M -271K -265K -11.41M
Net Debt	31.65K 22.19K 19.83K 18.5K 16.8K 2.15M 31.89K 222K 86.86K 1.09M 83.32K 81.52K 3.51M	17.3K 12.13K 10.84K 10.11K 9.18K 1.17M 17.42K 121K 47.46K 597K 45.53K 44.55K 1.92M